Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2171 in Hepatocellular Carcinoma
NCT00427973Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- May 2009
- Primary completion
- Apr 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cediranib in hepatocellular carcinoma (HCC), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 3 months. Started May 2009; status: terminated.
02
Drugs
cediranib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT00427973.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00427973.